Urea HC

Quick links to important sections

Urea HC

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urea HC

Property Description
Active ingredients Urea and Hydrocortisone
Form Topical Cream or Lotion
Pharmacological Class Topical Corticosteroid and Keratolytic Agent combination
General Purpose Soothing inflammation and softening rough, scaly skin
Origin Synthetic Pharmaceutical

Defining the Urea and Hydrocortisone Combination

The medication known as the Urea and Hydrocortisone combination is a topical prescription drug classified as a combination product that merges a mild steroid with a potent skin softener. This pharmaceutical preparation is designed for external use and is typically available as a topical cream or lotion. The formulation combines two distinct active ingredients: the glucocorticoid Hydrocortisone, and the keratolytic agent Urea (also known as carbamide). Hydrocortisone is a low-potency (Class 7) topical corticosteroid, making it a mild option among steroids.

The combination formulation is clinically recognized for its synergistic action in treating complex skin issues where both inflammation and hyperkeratosis (skin thickening) are present. The product is frequently sold under trade names such as Carmol HC or U-Cort, defining it as a specific, prescription-only topical therapy.


The Dual-Action Principle and General Purpose

The overall purpose of this dual-component medicine is to soothe skin discomfort and improve texture by addressing both the symptoms of inflammation and the condition of excessive scaling. Hydrocortisone contributes the anti-inflammatory and antipruritic (anti-itch) effect. Concurrently, Urea provides a strong keratolytic (skin-softening) and emollient action, which helps break down the rough, built-up layers of skin while significantly improving moisture retention.

Urea is recognized for its effectiveness in increasing skin hydration and promoting exfoliation of the stratum corneum, which is essential for treating dry and scaly skin conditions. This synergy means the preparation is generally intended to calm underlying inflammatory processes while simultaneously smoothing out dry, scaly skin.


Origin and Type: Is Urea HC a Synthetic Drug?

The Urea and Hydrocortisone combination is categorized as a synthetic pharmaceutical, meaning both of its active compounds are manufactured for medicinal use. Hydrocortisone is a synthetic version of the naturally occurring adrenal hormone cortisol, and Urea is chemically synthesized. This combined delivery ensures the synchronized application of both the anti-inflammatory agent and the deep moisturizer/softener within a single topical vehicle.

Regulatory References

  1. Topical Corticosteroids - NCBI Bookshelf

What side effects are possible with Urea HC?

The officially documented safety profile for the Urea and Hydrocortisone combination centers on local skin reactions and a potential, though infrequent, risk of systemic effects from the corticosteroid component. This information is based strictly on classifications from government regulatory documents.

Adverse Reaction Scope

Adverse Reaction Category Primary System-Organ Class Frequency Note
Local Dermatological Reactions Skin and Subcutaneous Tissue Disorders Primarily infrequent; Urea-related effects are typically transient.
Systemic Endocrine Effects Endocrine Disorders Recognized potential risk; exact frequency is not always classified.

Specific Safety Considerations

Commonly Documented Local Effects

The most frequent adverse reactions are related to the site of application and include burning, itching, dryness, and irritation. The prolonged use of the Hydrocortisone component may lead to skin atrophy (thinning), striae (stretch marks), or folliculitis.

Serious Adverse Reactions

Systemic absorption, especially with extensive or prolonged use, carries the serious documented risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome. Intracranial hypertension has also been reported in pediatric patients.

Population-Specific Safety

Pediatric patients demonstrate greater susceptibility to systemic toxicity due to their body composition, with documented outcomes including linear growth retardation and delayed weight gain. Caution is advised during pregnancy and lactation due to the potential for absorption.

Safety-Related Restrictions

Regulatory labeling explicitly states the product is contraindicated in individuals with a known hypersensitivity to any of its components. Furthermore, it should not be used in the presence of untreated primary bacterial, viral, or fungal diseases of the skin.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official regulatory profile for this topical combination defines risks associated with prolonged, excessive use and accidental ingestion. Over-application of the product may lead to sufficient systemic absorption of the hydrocortisone component to cause endocrine and metabolic disturbances.

Overdose Manifestations
Chronic Overuse Effects: Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, Manifestations of Cushing's syndrome, Hyperglycemia, Glucosuria.
Acute Ingestion Effects: Gastrointestinal irritation, nausea, and vomiting.

Accidental oral ingestion is the specific scenario that requires individuals to seek emergency medical attention as officially mandated. Although an acute topical overdose is not expected to produce life-threatening symptoms, suspected chronic overuse, particularly with signs of HPA axis suppression, requires consultation with a physician. Pediatric patients are officially documented to be more susceptible to systemic toxicity from topical corticosteroids. Management involves symptomatic and supportive care; no specific antidote is available. Treatment for chronic overexposure requires the gradual withdrawal or reduction of the product.

Therapeutic Uses of Urea HC

What Urea HC Treats: Main Uses and Benefits

The Urea and Hydrocortisone combination is a specialized topical therapy generally used for conditions presenting with systemic or localized discomfort where skin inflammation and significant textural changes occur together. It is applied across domains where additional symptomatic support is needed and contributes to easing the overall symptom load. Generally, corticosteroids are indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.


Managing Co-Existing Inflammation and Skin Thickening

This medication is commonly applied across conditions involving inflammatory or irritative processes, such as localized psoriasis, specific forms of eczema (dermatitis), and lichen planus, which involve both skin redness and dense, scaly plaques. It contributes to improved comfort during periods of heightened symptoms by managing the symptoms related to inflammatory or irritative states and helps reduce the uncomfortable roughness and thickness of the lesions.


Addressing Chronic Skin Textural Disorders

The preparation is considered relevant for conditions involving episodic or fluctuating manifestations such as ichthyosis or severe keratosis pilaris where the primary issue is persistent, excessive scaling and dryness. It supports the management of these chronic issues by assisting with the softening and management of symptoms related to texture, which helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Symptomatic Support for Dual Manifestations
This combination may be part of symptomatic management when symptoms include both intense itching (pruritus) and persistent skin thickening.

Regulatory References

  1. HYDROCORTISONE CREAM USP, 2.5% HYDROCORTISONE OINTMENT USP, 2.5% - DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Urea HC

Eligibility for Urea Hydrocortisone (Urea HC) is defined by regulatory authorities based on patient status and the risk of systemic absorption of the corticosteroid component.


Contraindications and Restrictions

Use is contraindicated for any patient with a documented history of hypersensitivity or allergy to Hydrocortisone, Urea, or any other component in the formulation. This medicine must not be used on individuals with known component allergies.


Age-Specific Eligibility

  • Pediatric Patients: Infants and children are more susceptible to systemic toxicity, such as HPA axis suppression, due to their higher skin surface area-to-body weight ratio. For certain combination products, use is not recommended in children under two years of age.
  • Geriatric Patients: For some formulations, the safety and effectiveness have not been established in patients over 65 years of age.

Pregnancy and Lactation

Topical use during pregnancy is conditional (Category C) and should be undertaken only if the potential benefit justifies the risk to the fetus; extensive use is prohibited. Caution must be exercised when administered to a nursing mother.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for the Urea and Hydrocortisone combination—a topical prescription medicine—indicates a minimal risk for systemic drug interactions when the product is used as directed. The interaction profile is primarily shaped by its low systemic absorption.

Documented Interaction Patterns

The most significant interaction pattern documented in regulatory labeling is related to additive exposure, not metabolic interference.

Interaction Type Interacting Substance/Condition
Pharmacodynamic Risk Other Corticosteroid-Containing Products (Topical or Systemic)
Exposure Modification Use of Occlusive Dressings

The official interaction profile is structured around the caution against the concurrent use of other corticosteroid preparations due to the potential for additive exposure. This measure is intended to minimize the combined systemic load of corticosteroids, which could otherwise increase the risk of systemic effects.

Furthermore, official prescribing information notes that procedural constraints, such as the use of occlusive dressings or application over a large surface area, can significantly augment the systemic absorption of the Hydrocortisone component, thereby modifying the overall exposure to the drug. No specific drug-drug interactions involving CYP enzymes, drug transporters, food, or alcohol are documented in official regulatory sources for this topical combination.

Mechanism of Action

Urea HC operates via a combined pharmacodynamic mechanism involving both its components. The urea component functions as a kerato-modifying agent and a potent humectant. It increases the water-binding capacity within the stratum corneum through an osmotic gradient, contributing to the modification of the epidermal barrier and enhancing the plasticity of the keratinized layer.

Concurrently, the hydrocortisone (HC) component, a low-potency corticosteroid, penetrates the cell membrane and binds to intracellular glucocorticoid receptors (GRs) in the cytoplasm. The resulting receptor-ligand complex translocates into the cell nucleus, where it acts as a transcription factor. This action modulates gene expression by transrepression, which decreases the transcription of messenger RNA for various pro-inflammatory mediators, including cytokines (such as interleukins and tumor necrosis factor) and chemokines. The resultant reduction in mediator synthesis limits the local recruitment and activation of immune and inflammatory cells at the site of application. The systemic consequence of this combined activity is a modulation of cell proliferation and differentiation within the epidermis, altering the physiological state of the affected tissue.

Dosage and Administration Information

How to Use Urea HC

The Urea and Hydrocortisone combination product is intended for topical, external use as a cream or lotion. Guidelines typically specify applying a thin film of the preparation to the affected skin area. Standard application generally involves use two to three times daily (bid to tid), and the skin should be cleaned before application.


Application and Treatment Course

Usage Principle Standard Administration
Route and Form Topical use only, typically as a cream or lotion.
Dosing Frequency Apply a thin film to the affected area two to three times daily.
Application Specifics Gently rub in completely; avoid contact with eyes, lips, and mucous membranes.

Short-term use is typically emphasized for this combination, with therapy generally limited to a specified course duration, such as a maximum of four weeks. Treatment is usually discontinued once the desired clinical control of the skin condition is achieved.


Use Constraints

The most important administration constraint is the rule against using occlusive dressings. The treated area should not be covered or wrapped with any occlusive material unless a healthcare specialist specifically directs it. Furthermore, continuous long-term therapy must be avoided in all patient populations, particularly in children and infants, where use is minimized due to their increased susceptibility to systemic effects from topical corticosteroids. If the lotion form is used, it should be shaken well before application.

Recent Clinical Evidence

Research evidence / Overview of Studies for Urea HC

The research available for the Urea and Hydrocortisone combination is structured around clinical studies, including Randomized Controlled Trials (RCTs). The evidence base includes studies that monitored symptom patterns and short-term clinical measures as evaluated by investigators.


Evidence for Use in Atopic Dermatitis (Eczema)

Research examining the Urea and Hydrocortisone combination was studied primarily in the context of atopic dermatitis (eczema). The evidence base includes controlled studies that examined the combination in conditions presenting with cycles of stability and flare-ups.

Study Design and Measured Outcomes for Eczema

Clinical evaluations were conducted using short-term RCTs, with some trials using a half-sided comparison design. Studies were designed to examine metrics related to overall disease severity as assessed by physicians. Specific outcomes linked to inflammatory or irritative states were studied, such as itching (pruritus), scaling, oozing, and skin thickening (lichenification). Research included both adults and children. Studies monitored and reported how symptoms evolved in the observed populations over follow-up periods that were typically short-term.


Evidence for Use in Corticosteroid-Responsive Dermatoses

Studies examined the combination in the broader category of non-infective, inflammatory skin conditions known as corticosteroid-responsive dermatoses. The research examined outcomes related to physical discomfort and symptom severity during periods of heightened activity. This body of research primarily focuses on the initial response within the first few weeks of use.


Long-Term Studies and Follow-Up Duration

The follow-up durations for many controlled clinical trials were limited, primarily focusing on short-term assessment over a few weeks. However, long-term effects regarding the maintenance of observed outcomes are not fully established by formal, extended RCTs.


What is Still Uncertain About the Research for Urea HC

The research highlights what is known and what is still uncertain within the evidence landscape. Evidence quality varies across studies, and the sample sizes used in many key comparative trials were modest. The data for certain groups, particularly with respect to long-term effects, are not fully established.

Key Studies & References

  1. HYDROCORTISONE CREAM USP, 2.5% HYDROCORTISONE OINTMENT USP, 2.5% - DailyMed (Regulatory Monograph)
  2. Urea-containing creams in the treatment of dry skin
  3. Topical treatment with urea-hydrocortisone in atopic dermatitis
  4. [Results and consequences of long-term urea therapy for clinical practice]

Frequently Asked Questions (FAQ)

Common questions about Urea HC (FAQ)

Q: Can Urea HC cause stinging or burning on the skin?

A: Yes, official safety information documents that burning, stinging, itching, and irritation at the application site are among the local adverse effects commonly observed. These are generally related to the site of application.


Q: Can Urea HC be used on the face?

A: Official precautions advise caution when applying this combination product to the face. Use on the face can increase the risk of systemic absorption and is also associated with a higher risk of local side effects, such as skin thinning. Official guidance emphasizes the need for consultation with a healthcare provider before use on this area.


Q: What happens if Urea HC is used on broken or severely irritated skin?

A: Official guidance cautions against application to areas with cuts, scrapes, severe injuries, or broken skin. Regulatory information notes that use on compromised skin may enhance the absorption of the corticosteroid component, which could increase the chance of systemic side effects.


Q: Does using Urea HC make the skin more sensitive to the sun?

A: Standard regulatory documents for the active ingredients, urea and hydrocortisone, do not typically list them as photosensitizing drugs. However, some specific product formulations may contain additional ingredients that carry warnings about sun sensitivity. It is recommended to review the patient information for the specific product being used.


Q: What is the maximum duration of use generally mentioned in official information?

A: Regulatory documents specify that this product is intended for a short-term use pattern. The maximum length of treatment course often cited in official administration protocols is up to four continuous weeks, and treatment should stop promptly once the skin condition is controlled.


Q: Does Urea HC interact with common blood pressure medicines?

A: Regulatory documents report a minimal risk for systemic drug-drug interactions when the product is used topically as directed. Official sources generally do not list specific severe or moderate interactions with common systemic medicines like those for blood pressure.


Q: Can Urea HC affect blood sugar levels?

A: Systemic absorption, particularly with extensive or prolonged use, carries a risk of effects on the endocrine system. Official warnings document the potential for manifestations of hyperglycemia (high blood sugar) and glucosuria (sugar in the urine).


Q: Does Urea HC have a risk of systemic absorption?

A: Yes, regulatory information indicates that topical corticosteroids can be absorbed through the skin and into the bloodstream. Conditions such as application over a large surface area or under an occlusive dressing can significantly augment this systemic absorption.


Q: How quickly should someone expect to notice changes after starting Urea HC?

A: Official information may set a time frame for reassessment of the condition. For example, some documents indicate that if no improvement is observed within a certain short time frame, such as two weeks, consultation with a healthcare professional may be indicated to reassess the diagnosis.


Q: What types of ingredients should be avoided when using Urea HC?

A: Guidance cautions against the concurrent use of other corticosteroid preparations because of the risk of additive systemic exposure. Furthermore, patient information often advises caution when using other skin care products or cosmetics on the treated areas.


Q: Are there any long-term research studies on the use of Urea HC?

A: Controlled clinical trials for the product have focused primarily on short-term assessment over a few weeks. Official documentation notes that the long-term effects regarding the maintenance of positive outcomes are not fully established by formal, extended studies.


Q: Is there a generic version of Urea HC available?

A: The medicine, which is a combination of urea and hydrocortisone, is marketed under various brand names. Depending on regulatory approval status, the product may also be widely available in generic forms.


Q: Can Urea HC cause skin thinning over a long period?

A: Yes, regulatory warnings note that skin atrophy (thinning) is a documented adverse reaction. This condition is associated with the prolonged or extensive use of the Hydrocortisone component in the combination product.


Q: What is the primary mechanism by which Urea HC reduces redness?

A: The reduction of redness is primarily achieved through the anti-inflammatory effect provided by the Hydrocortisone component. This steroid works by modulating gene expression to decrease the transcription of pro-inflammatory mediators in the skin.


Q: Are there any documented cases of allergic reactions to Urea HC?

A: The product is contraindicated (should not be used) for anyone with a known hypersensitivity or allergy to any of its ingredients. Allergic contact dermatitis is also listed in official documentation as a potential adverse reaction.


Q: Do official documents mention any potential for withdrawal symptoms if use is stopped suddenly?

A: Guidance on topical corticosteroids notes that sudden discontinuation, especially after prolonged use, may be associated with rebound or withdrawal reactions. For this reason, official patient guidance indicates that cessation of use should be discussed with a healthcare professional.


Q: Can Urea HC be used at the same time as medicated cleansers?

A: Patient guidance generally advises caution regarding the use of other skin care products, including medicated cleansers, on the areas being treated with Urea HC. This is generally stated to avoid potential additive effects on the treated area.


Q: What does 'occlusion' mean in relation to using a product like Urea HC?

A: In the context of topical medication, occlusion refers to covering or wrapping the treated skin area. This includes materials like bandages, medical tape, or other dressings that trap the product against the skin.


Q: Are there different strengths or formulations of Urea HC?

A: Official labeling documents that the medication is available in different topical forms, typically as a cream or a lotion. The specific strengths of urea and hydrocortisone may also vary depending on the product brand and regulatory approval.


Q: How is Urea HC intended to be different from a simple urea-only cream?

A: The key difference is the addition of the hydrocortisone component. This component provides a mild anti-inflammatory and anti-itch (antipruritic) effect that is not found in a simple urea-only cream, which focuses solely on moisturizing and keratolytic action.


Q: What are common informational descriptions of drug interactions involving Urea HC?

A: Official sources note a minimal risk for systemic drug interactions when used correctly. The primary concern documented is the caution against the concurrent use of other corticosteroid products due to the risk of additive systemic exposure.

How should Urea HC be stored and disposed of?

How to Store and Dispose of Urea and Hydrocortisone (Urea HC)

The storage and disposal of this topical medication are strictly governed by regulatory requirements to ensure product stability and safety.

Official Storage Conditions

Urea HC products must be stored at Controlled Room Temperature, typically maintained between 20°C to 25°C (68°F to 77°F). It is mandatory to protect the medication from freezing and excessive heat at all times. The container must be kept tightly closed to prevent contamination and evaporation. As with all medications, it must be stored securely and kept out of the reach of children.

Disposal Instructions

Unused or expired Urea HC must be disposed of according to local regulations for pharmaceutical waste. Unless otherwise instructed by a government-mandated take-back program, the product should generally not be flushed down a toilet or poured into a drain to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Urea HC found in:

A-Z Index: